Table 1. Patient, tumor, and treatment characteristics (N=90).
| Characteristic | No. (%) or median [range] |
|---|---|
| Age | 55 [27–80] |
| Gender | |
| Male | 52 (57.8%) |
| Female | 38 (42.2%) |
| Ethnicity | |
| White | 83 (92.2%) |
| Black | 3 (3.3%) |
| Other | 4 (4.4%) |
| KPS | |
| 90–100 | 80 (88.9%) |
| 70–80 | 10 (11.1%) |
| Clinical T-Stage | |
| cT2 | 3 (3.3%) |
| cT3 | 80 (88.9%) |
| cT4 | 7 (7.8%) |
| Clinical N-Stage | |
| cN0 | 29 (32.2%) |
| cN1 | 48 (53.3%) |
| cN2 | 13 (14.4%) |
| Radiation technique | |
| 3DCRT | 82 (91.1%) |
| IMRT | 8 (8.9%) |
| Total dose (cGy) | |
| 5,600 | 7 (7.8%) |
| 5,040 | 78 (86.7%) |
| 5,000 | 3 (3.3%) |
| 4,860 | 1 (1.1%) |
| 4,500 | 1 (1.1%) |
| Neoadjuvant chemotherapy | |
| 5FU | 42 (46.7%) |
| Capecitabine | 29 (32.2%) |
| 5FU + Sorafenib | 9 (10.0%) |
| Capecitabine + Lenvantinib | 7 (7.8%) |
| FOLFOX | 2 (2.2%) |
| Capecitabine + Oxaliplatin | 1 (1.1%) |
| Interval between completion of neoadjuvant treatment and surgery (days) | 61.5 [36–105] |
| Surgery | |
| LAR | 73 (81.1%) |
| APR | 17 (18.9%) |
| Adjuvant chemo | |
| FOLFOX | 58 (64.4%) |
| Capecitabine + Oxaliplatin | 13 (14.4%) |
| 5FU | 5 (5.6%) |
| Capecitabine | 5 (5.6%) |
| FOLFOX + Avastin | 1 (1.1%) |
| None | 8 (8.9%) |
| Pathologic T-stage | |
| ypT0 | 24 (26.7%) |
| ypT1 | 3 (3.3%) |
| ypT2 | 23 (25.6%) |
| ypT3 | 38 (42.2%) |
| ypT4 | 2 (2.2%) |
| Pathologic N-stage | |
| ypN0 | 53 (58.9%) |
| ypN1 | 26 (28.9%) |
| ypN2 | 11 (12.2%) |
| NAR score | |
| <8 | 29 (32.2%) |
| 8 to 16 | 28 (31.1%) |
| >16 | 33 (36.7%) |
| TRG | |
| 0 | 21 (23.3%) |
| 1 | 47 (52.2%) |
| 2 | 18 (20.0%) |
| 3 | 4 (4.4%) |
| Differentiation | |
| Well/moderate | 88 (95.7%) |
| Poor | 4 (4.3%) |
| LVI | 25 (27.8%) |
| PNI | 19 (21.1%) |
| Distance to anal verge (cm) | 5 [0–15] |
| Pretreatment longitudinal tumor size (cm) | 5 [1.5–11] |
| Circumferential radial margin | |
| Positive | 6 (6.7%) |
| Negative | 84 (93.3%) |
| Distal resection margin | |
| Positive | 1 (1.1%) |
| Negative | 89 (98.9%) |
| Completeness of mesorectum | |
| Complete | 53 (58.9%) |
| Near complete | 14 (15.6%) |
| Incomplete | 4 (4.4%) |
| N/A | 19 (21.1%) |
KPS, Karnofsky Performance Status; 3DCRT, three-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; cGy, centigray; 5FU, fluorouracil; FOLFOX, fluorouracil, oxaliplatin, leucovorin; LAR, low anterior resection; APR, abdominoperineal resection, NAR, neoadjuvant rectal score; TRG, tumor regression grade; LVI, lymphovascular invasion; PNI, perineural invasion; N/A, not available.